Edwards Lifesciences Corporation (NYSE:EW) Receives $96.14 Average Price Target from Brokerages

Shares of Edwards Lifesciences Corporation (NYSE:EW) have earned an average recommendation of “Moderate Buy” from the twenty-seven analysts that are currently covering the company, Marketbeat reports. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $96.1364.

Several equities research analysts recently issued reports on EW shares. BTIG Research reaffirmed a “buy” rating and issued a $103.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a report on Monday, January 12th. Stifel Nicolaus set a $110.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, January 20th. JPMorgan Chase & Co. upgraded Edwards Lifesciences from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $90.00 to $100.00 in a research note on Thursday, December 18th. Finally, Truist Financial set a $89.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday, February 11th.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $85.93, for a total value of $974,446.20. Following the completion of the sale, the vice president directly owned 21,266 shares in the company, valued at approximately $1,827,387.38. The trade was a 34.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,371,239.08. This represents a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 61,718 shares of company stock valued at $5,236,281 over the last 90 days. 1.29% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of EW. Brighton Jones LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $266,000. Atlantic Union Bankshares Corp acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at approximately $40,000. Modera Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at approximately $221,000. Savant Capital LLC increased its position in Edwards Lifesciences by 16.4% in the 2nd quarter. Savant Capital LLC now owns 25,842 shares of the medical research company’s stock worth $2,021,000 after buying an additional 3,637 shares during the period. Finally, AE Wealth Management LLC increased its position in Edwards Lifesciences by 1.4% in the 2nd quarter. AE Wealth Management LLC now owns 91,755 shares of the medical research company’s stock worth $7,176,000 after buying an additional 1,253 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.6%

NYSE:EW opened at $84.62 on Tuesday. The company has a market capitalization of $49.15 billion, a P/E ratio of 46.24, a P/E/G ratio of 2.22 and a beta of 0.93. The stock’s 50 day moving average price is $82.48 and its 200 day moving average price is $81.57. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. Edwards Lifesciences has a 52 week low of $65.94 and a 52 week high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. During the same quarter last year, the firm earned $0.59 earnings per share. Edwards Lifesciences’s revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts forecast that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.